Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | MARS1 | P56192 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPID | Q08752 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4374693 | 0.83 | NLRP3 (0.38) | NLRP3MARS1MEN1KMT2APPID | |
| SCHEMBL2998076 | 0.83 | NLRP3 (0.48) | NLRP3NR4A1EGFR | |
| SCHEMBL2998422 | 0.69 | NLRP3 (0.46) | NLRP3MEN1KMT2A | |
| Racemethionine SCHEMBL28105893 | 0.67 | ALDH1A1 (0.47) | — | |
| SCHEMBL3000425 | 0.66 | NLRP3 (0.43) | NLRP3MEN1KMT2A | |
| Racemethionine SCHEMBL27865038 | 0.65 | METAP2 (0.43) | — | |
| Racemethionine SCHEMBL27686953 | 0.64 | BHMT (0.53) | KMT2A | |
| Racemethionine SCHEMBL23361954 | 0.64 | BHMT (0.57) | KMT2A | |
| Racemethionine SCHEMBL8983115 | 0.64 | BHMT (0.57) | KMT2A | |
| Methionine SCHEMBL5584463 | 0.64 | BHMT (0.57) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2070921-A1 | Indolylmaleimide derivatives as protein kinase c inhibitors | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | NLRP3 210/4885NR4A1 1121/4885MARS1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.